Available Technologies

Browse Penn-owned technologies available for licensing.


Search Results - daniel powell

3 Results Sort By:
CAR T cell therapy for the treatment of ovarian cancer and other gynecologic malignancies
Anti-Mullerian inhibiting substance type II receptor (MISRII) specific CAR T cell therapy for the targeted, safe treatment of ovarian cancer. Technology Overview: Ovarian cancer is the 5th leading cause of cancer-related deaths in women and is the most lethal of all gynecologic malignancies with an overall 5-year survival rate of 46%. The Müllerian...
Published: 3/11/2020   |   Inventor(s): Daniel Powell, Alba Rodriguez-Garcia
Category(s): Therapeutics & Vaccines
Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells
The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...
Published: 1/29/2020   |   Inventor(s): Daniel Powell
Keywords(s): Antibody, Autoimmune, Cell Therapy, Immunology, Immunoncology, Oncology
Category(s): Therapeutics & Vaccines
Single viral vector for expression of both CAR/TCR and immune modulators for cancer immunotherapy
A single lentiviral vector system as an expression platform for constitutive immune receptor expression and inducible antigen-dependent immunomodulatory molecule expression in primary immune cells for enhanced immunotherapy efficacy Problem: Adoptive cancer immunotherapy, like chimeric antigen receptor T cell (CAR T) therapy, has had extraordinary...
Published: 1/23/2019   |   Inventor(s): Daniel Powell, Anze Smole, Avery Posey
Category(s): Research Tools & Reagents, Therapeutics & Vaccines